Diapin Therapeutics LLC
Biotech · Private
ClopNPT, a novel clopidogrel conjugate molecule that releases active metabolite via glutathione rather than CYP enzymes for improved antiplatelet therapy
- Grants
- $4.6M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 1 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of DT-109 as an oral therapeutic for type 2 diabetes | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DT-110 as an oral therapeutic for type 2 diabetes | $765,902 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of DT-109 as an oral therapeutic for type 2 diabetes | $990,902 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of DT-110 as an oral therapeutic for type 2 diabetes | $1,490,762 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DT-110 as an oral therapeutic for type 2 diabetes | $724,860 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel ClopNPT for the treatment of acute coronary syndrome | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel ClopNPT for the treatment of acute coronary syndrome | $225,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2812 | A2 Biotherapeutics | — | $119M |
| 2813 | Interius BioTherapeutics | — | $118M |
| 2814 | TAMBO, INC. | — | — |
| 2815 | Diapin Therapeutics LLC | — | — |
| 2816 | Mineralys Therapeutics, Inc. | — | $118M |
| 2817 | LYST THERAPEUTICS LLC | — | — |
| 2818 | Relation Therapeutics | — | $116M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Treatment Of Diabetes Using Agonists Of The Mas-related Gpcr Dapplication
- Treatment of Type 2 Diabetes With FTY720granted
- Treatment Of Diabetes Using Agonists Of The Mas-related Gpcr Dapplication
- Treatment Of Diabetes Using Agonists Of The Mas-related Gpcr Dapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.